Skip to content
Navigate to homepage - Cerba Research

Case Study – Phase 2 To Determine Safety And Efficacy Of A mAB CKI Combo In Relapse Refractory Multiple Myeloma (RRMM)

Discover how we managed cell isolation and counts among other routine and speciality tests for a large Relapse Refractory Multiple Myeloma  study over 11,000 samples managed.

Tests including FCM, PBMC isolation and count, FISH

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us